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Summary
Background Whether antihypertensive drugs offer
cardiovascular protection beyond blood pressure lowering
has not been established. We aimed to investigate whether
pharmacological properties of antihypertensive drugs or
reduction of systolic pressure accounted for cardiovascular
outcome in hypertensive or high-risk patients.
Methods In a meta-analysis we extracted summary statistics
from published reports, and calculated pooled odds ratios for
experimental versus reference treatment. We correlated
across-trials odd ratios for differences in systolic pressure
between groups.
Findings We analysed nine randomised trials comparing
treatments in 62 605 hypertensive patients. Compared with
old drugs (diuretics and -blockers), calcium-channel
blockers and angiotensin converting-enzyme inhibitors
offered similar overall cardiovascular protection, but calcium-
channel blockers provided more reduction in the risk of
stroke (13·5%, 95% CI 1·3–24·2, p=0·03) and less reduction
in the risk of myocardial infarction (19·2%, 3·5–37·3,
p=0·01). Heterogeneity was significant between trials
because of high risk of cardiovascular events on doxazosin in
one trial, and high risk of stroke on captopril in another; but
systolic pressure differed between groups in these two trials
by 2–3 mm Hg. Similar systolic differences occurred in a trial
of diltiazem versus old drugs, and in three trials of
converting-enzyme inhibitor against placebo in high-risk
patients. Meta-regression across 27 trials (136 124
patients) showed that odds ratios could be explained by
achieved differences in systolic pressure.
Interpretation Our findings emphasise that blood pressure
control is important. All antihypertensive drugs have similar
long-term efficacy and safety. Calcium-channel blockers
might be especially effective in stroke prevention. We did not
find that converting-enzyme inhibitors or -blockers affect
cardiovascular prognosis beyond their antihypertensive
effects.
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Introduction
Lifetime risk of hypertension is about 20%. Several trials
have been done to find the best possible protection against
the cardiovascular complications of this widespread
condition. Various drugs were tested to see whether their
mode of action or ancillary properties could offer benefit
beyond their effect of lowering blood pressure.1–16 In
normotensive and hypertensive high-risk patients in the
HOPE study,7 the angiotensin-converting enzyme (ACE)
inhibitor ramipril significantly reduced rates of death,
stroke, and myocardial infarction compared with placebo.
In hypertensive patients enrolled in ALLHAT,10 fewer
cardiovascular events happened during treatment with
chlorthalidone than with the -blocker doxazosin.
However, in both studies,7,10 systolic pressure was 
2–3 mm Hg lower in the group with the best outcome,
which could have been sufficient to explain the results.17–19
Two quantitative overviews20,21 reached opposite
conclusions with respect to cardiovascular protection of
calcium-channel blockers compared with diuretics or -
blockers. However, neither of these overviews20,21
specifically assessed blood pressure differences between
randomised groups in relation to heterogeneity among
trials, or included -blockers in the group of newer drugs. 
We investigated whether pharmacological properties of
antihypertensive drugs or blood pressure reduction
explained cardiovascular outcome. We focused on systolic
pressure because, in middle-aged and older patients,
systolic pressure is a better predictor of cardiovascular risk
than diastolic pressure,22 and systolic pressure can be
measured more reliably than diastolic pressure.23 First, we
assessed whether differences in achieved systolic pressure
between randomised groups led to heterogeneity among
outcome trials of old versus new classes of
antihypertensive drugs. Second, we used metaregression
to measure to what extent blood pressure reduction
accounts for results of outcome trials.
Methods
Trials
We searched for outcome trials that tested drugs to lower
blood pressure in normotensive or hypertensive patients
who did not have overt heart failure at enrolment. Other
inclusion criteria were a randomised controlled design,
publication in a peer-reviewed journal, inclusion of
patients with hypertension, assessment of blood pressure
and cardiovascular events, follow-up of 2 years or longer,
and sample size of 100 or more. Outcome trials of drugs
to lower blood pressure were identified from previous
overviews17,18,20,21,24,25 and from a Medline search for trials
with expected publication date before 2001.25
For the first part of our review, we selected outcome
trials in hypertensive patients that compared old classes of
antihypertensive agents, such as diuretics or -blockers,
with new agents such as calcium-channel blockers, ACE
inhibitors, or -blockers. We identified 11 such
studies.1–6,8–10,14,16 We excluded one trial1 because
randomisation was not between old and new drugs but
between special intervention and usual care, and a second
study2 because cardiovascular outcome data were
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published only in aggregate form. In our analysis, we
combined three small trials3,5,14 that tested a calcium-
channel blocker against a thiazide; in these trials less than
40 cardiovascular events occurred in 414 Japanese
patients followed up for 5 years,5 or less than one event
per 1000 patient-years.3,14
To study the relation between odds ratios of
experimental versus reference treatment, and the
corresponding baseline-corrected blood pressure
differences, we included the nine trials in hypertensive
patients that we selected for the first part of our
overview,3–6,8–10,14,16 two reports comparing tight with
relaxed blood pressure control,26,27 11 older studies in
patients with systolic or diastolic hypertension comparing
active treatment with no treatment28,29 or with placebo,30–38
three placebo-controlled studies in isolated systolic
hypertension,39–41 and three placebo-controlled trials of
ACE inhibitors in normotensive and hypertensive patients
at high cardiovascular risk.7,12,15 Among these 27 studies,
two had a single-blind design with alternate allocation of
consecutive patients to placebo or active treatment.34,41 We
excluded from our metaregression seven small trials in
hypertension,42–48 which (in keeping with our exclusion
criteria) accumulated fewer than 100 patients46–48 or less
than 2 years of follow-up,43,45 or did not provide
information on systolic pressure44 or cardiovascular
events.42 Because blood pressure, in particular systolic
pressure,49 was not reported, we also excluded the HDFP
study49 and two placebo-controlled trials on progression of
atherosclerotic disease under treatment with quinapril11 or
amlodipine.13 Because of similarity in design and few
events we combined four small trials published in 1980 or
before,29,36–38 and two placebo-controlled trials on
progression of atherosclerosis with use of ACE
inhibitors.12,15
We did not include trials that compared old with old
drugs (ie, -blockers with diuretics)50–52 or new with new
compounds (ie, ACE inhibitors with calcium-channel
blockers),53,54 because we could pool only few studies in
outcome analysis, and because in metaregression analysis
it was clinically difficult to define what was the reference
treatment for calculation of odds ratios. 
Outcomes
We based our analysis on the summary statistics
published in 37 reports3–10,12,14–16,26–41,55–63 on the 27 selected
trials. Apart from fatal combined with non-fatal events in
the EWPHE trial,30,55 all outcome results were reported on
the basis of an intention-to-treat principle. EWPHE was
one of the first intervention studies on treatment of
hypertension and was planned in 1971. Patients who were
randomised and who left the double-blind part of the
study were followed up until July 1, 1984, but only date
and cause of death were recorded. 
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Characteristic Trials 
UKPDS16,27* STOP26 CAPPP4 NORDIL9 INSIGHT8 ALLHAT10 MIDAS3 NICS5 VHAS63†
Masking type Open Open Open Open Double Double Double Double Open 
Number of patients 1148 6614 10985 10881 6321 24335 883 414 1414 
Treatment
Reference Atenolol HCTZ/A or Diuretic or Thiazide or HCTZ/A Chlorthali- HCTZ Trichlorme Chlorthali-
<180/105 -blockers -blockers -blockers done thiazide done 
Experimental Captopril ACEIs Captopril Diltiazem Nifedipine Doxazosin Isradipine Nicardipine Verapamil 
<150/85 DHPs (SR) (GITS) (SR) (SR) 
Age (mean [SD], years) 56 (8) 76 (··) 53 (8) 60 (7) 65 (7) 67 (8) 59 (9) 70 (7) 53 (7)
Mean systolic/diastolic blood 
pressure (mm Hg)
At entry 160/94 194/98 161/99 173/106 167/96 145/83‡ 150/97 172/94 169/102 
Difference during follow-up§ –1/–1 –0·3/+0·5 –3/–1 –3·1/+0·2 0/0 –2/+1 –3·5/0 –0·7/–1·2 –1·0/+0·4
Proportion of patients (%)
Women 45 67 47 51 54 47 22 67 51 
Cardiovascular complications ·· 20 4 8 20 45 4 28 5 
Diabetes mellitus 100 11 5 7 21 36 ·· ·· 4
Follow-up (years) 
Median 8·4 ·· ·· ·· ·· 3·3 3·0 4·3 2·0
Mean ·· 5·0 6·1 4·5 3·5 ·· ·· ·· ··
ACEIs=angiotensin-converting enzyme inhibitors; DHPs=dihydropyridine calcium-channel blockers (felodipine or isradipine); GITS=gastro-intestinal therapeutic system;
HCTZ=hydrochlorothiazide; HCTZ/A=hydrochlorothiazide plus amiloride; SR=sustained release. Acronyms of trials are explained in the appendix. *UKPDS compared
captopril with atenolol and tested two levels of control of systolic/diastolic blood pressure. †In VHAS, study drug was given in a double-blind fashion during the initial 6
months and thereafter in an open way. ‡90% of ALLHAT patients had blood pressure measured at entry while on antihypertensive treatment. §Negative values indicate
tighter blood pressure control on old drug classes. Patients on antidiabetic drug treatment. 
Table 1: Characteristics of trials in hypertension comparing different active treatments 
Zelen’s Pooled estimates of advantage of
p-value* new versus old drugs expressed
in percent†
Estimate (SD) 95% CIs p 
Cause of death‡
Stroke
CCBs 0·95 –5·3 (17·9) –31·4 to 30·7 0·79
ACEIs 0·89 –5·6 (18·6) –32·5 to 31·8 0·79
CCBs and ACEIs 0·99 –5·4 (14·0) –26·8 to 22·5 0·70
Myocardial infarction
CCBs 0·13 22·6 (16·6) –9·2 to 65·8 0·19
ACEIs 0·32 –6·3 (15·1) –28·9 to 23·4 0·68
CCBs and ACEIs 0·10 7·9 (12·1) –13·6 to 35·0 0·53
Sudden death 
CCBs 0·46 –8·8 (18·4) –34·5 to 26·8 0·64
ACEIs 0·07 3·8 (19·3) –26·5 to 46·7 0·89
CCBs and ACEIs 0·12 –5·3 (15·1) –28·0 to 25·1 0·74
Myocardial infarction plus sudden death 
CCBs 0·92 7·9 (12·2) –13·8 to 35·2 0·53
ACEIs 0·07 –2·5 (11·6) –21·4 to 20·9 0·85
CCBs and ACEIs 0·20 2·5 (9·3) –13·8 to 22·1 0·81
ACEIs=angiotensin-converting enzyme inhibitors; CCBs=calcium-channel
blockers. *The hypothesis of heterogeneity across the reviewed trials was
rejected for all fatal outcomes. †Negative values indicate better outcome on
the new drugs. ‡The reviewed trials are those listed in table 1 with the
exception of ALLHAT, because cardiovascular mortality was unavailable from
the published report.10 Cause-specific cardiovascular mortality was also not
reported for MIDAS,3 NICS,5 and VHAS.63
Table 2: Pooled estimates of advantage of new versus old
antihypertensive drugs with respect to cause-specific mortality
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For comparison between old and new drugs, we
extracted from nine reports3–6,8–10,14,16 the number of deaths
from myocardial infarction, including and excluding
sudden death, stroke, and all cardiovascular causes.
Additionally, we noted the number of cardiovascular
events, fatal and non-fatal strokes excluding transient
ischaemic attacks, fatal and non-fatal myocardial
infarctions, and fatal and non-fatal cases of congestive
heart failure. For metaregression, we used only those
events that could be consistently extracted from published
reports3–10,12,14–16,26–41,55–63 on the 27 trials.
We had to accept the definitions of events used by the
study investigators. In seven trials,4,6,7,9,15,26,31 the term all
cardiovascular events refers to the primary composite
endpoint. In Syst-Eur40,59,60 and Syst-China41,61 trials we
used individual records of patients and the published
definition of all cardiovascular events. For the other
studies, we summed major cardiovascular events. Since
more than one event might have happened to an
individual, this approach is likely to have resulted in slight
overestimation of the total number of patients with
cardiovascular complications.
Statistical analyses 
We assessed the relative benefit of experimental versus
reference treatment from odds ratios in stratified 22
contingency tables.17,18 In every trial, the reference group was
patients who were left untreated28,29 or allocated
placebo,7,12,30–41 or patients randomly assigned old classes of
drugs3–6,8–10,14,16 or a treatment strategy leading to poor blood
pressurecontrol.26,27
We used StatXact for Windows (version 4.0), to check
homogeneity of odds ratios by Zelen’s test, andtocalculate
exact 95% CIs. To enable comparisons with other
overviews,17,18,20,21,24 we also derived SDs of pooled odds
ratios by analogy withtheasymptotic approach by division
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Figure 1: Effects of antihypertensive treatment on cardiovascular mortality and all cardiovascular events in trials comparing old with
new drugs 
Solid squares=treatment-to-control odds ratios in trials and have a size proportional to number of events. 95% CI for individual trials are denoted by lines
and those for pooled odds ratios by diamonds. Acronyms and references of trials are in the appendix.
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of the exact logarithmically transformed 95% CI by
(21·96). All pvalues are for two-sided tests.
We used the SAS statistical package (version 6.12), to
correlate odds ratios of experimental versus reference
treatment with corresponding blood pressure
differences. For these calculations, odds ratios were
logarithmically transformed. The regression lines were
weighted by the inverse of the variance of individual
odds ratios. Net treatment effects on blood pressure
were calculated by subtraction of the mean change in
the experimental group (follow-up minus baseline)
from the corresponding mean change in the reference
group. If blood pressure at entry differed between
groups in the same study, the average pressure was
taken as baseline.4
Results
Heterogeneity
We assessed heterogeneity in results of trials comparing
old with new antihypertensive drugs (table 1). The trials
included 33 325 patients randomly assigned old drugs
and 29 280 assigned initial antihypertensive treatment
with new drugs. 
Because the ALLHAT report10 did not include separate
information on cardiovascular mortality, this trial could
not be included in the review of fatal endpoints (figure 1
and table 2). Cause-specific cardiovascular mortality was
not reported for MIDAS,3 NICS,5 or VHAS.63 In trials
with information on one or more of the fatal
outcomes,3–6,8,9,16,63 such outcomes did not differ between
new and old drugs apart from a 3·22 (95% CI 1·12–11·2,
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Figure 2: Effects of antihypertensive treatment on fatal and non-fatal stroke and myocardial infarction in trials comparing old with
new drugs 
Fatal and non-fatal myocardial infarction includes sudden death. Acronyms and references of trials are in the appendix.
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Figure 3: Effects of antihypertensive treatment on fatal and non-fatal congestive heart failure in trials comparing old with new drugs 
Acronyms and references of trials are in the appendix.
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Figure 4: Relation between odds ratios for cardiovascular mortality and all cardiovascular events, and corresponding differences in
systolic blood pressure 
Odds ratios were calculated for experimental versus reference treatment. Blood pressure differences were calculated by subtracting achieved levels in
experimental groups from those in reference groups. Negative differences indicate tighter blood pressure control on reference treatment. Regression
lines were plotted with 95% CI and were weighted for the inverse of the variance of individual odds ratios. Closed symbols denote trials that compared
new with old drugs. Acronyms and references of trials are in the appendix.
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p=0·03) increase in fatal myocardial infarction on
treatment with nifedipine GITS (gastrointestinal transfer
system).8 Heterogeneity was not significant by Zelen’s test
in any of the pooled mortality results (table 2). The new
drugs were as effective as the old ones in prevention of
cardiovascular mortality or deaths from stroke and
myocardial infarction with or without sudden death. 
With respect to fatal combined with non-fatal
outcomes, trials had significant heterogeneity, which was
largely attributable to higher risk of cardiovascular
complications (figure 1), stroke (figure 2), and congestive
heart failure (figure 3) with doxazosin than with
chlorthalidone in ALLHAT.10 For these events, odds
ratios were 1·25 (1·17–1·33, p0·0001), 1·19 (1·01–1·40,
p=0·04), and 2·04 (1·79–2·32, p0·0001), respectively.10
After exclusion of ALLHAT, slight heterogeneity
persisted in overall risk of cardiovascular complications
with ACE inhibitors compared with old drugs (figure 1,
p=0·03). This result was attributable to higher risk of
stroke4 in patients randomly assigned captopril (figure 2):
odds ratio 1·25 (1·01–1·55, p=0·04). In individual trials,
patients allocated diltiazem9 had a lower risk of stroke
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Figure 5: Relation between odds ratios for fatal and non-fatal stroke and fatal and non-fatal myocardial infarction, and
corresponding differences in systolic blood pressure 
Fatal and non-fatal myocardial infarction includes sudden death. Odds ratios were calculated for experimental versus reference treatment. Blood pressure
differences were calculated by subtracting achieved levels in experimental groups from those in reference groups. Negative differences indicate tighter blood
pressure control on reference treatment. Regression lines were plotted with 95% CI and were weighted for the inverse of the variance of individual odds
ratios. Closed symbols denote trials that compared new with old drugs. Acronyms and references of trials are in the appendix.
Variance explained and corresponding probability 
Overall model Initial blood pressure Blood pressure difference 
R2 p R2 p R2 p
Outcome
Cardiovascular mortality 
Systolic 0·47 0·002 0·11 0·05 0·36 0·0004
Diastolic 0·42 0·005 0·10 0·08 0·32 0·001
Cardiovascular events 
Systolic 0·66 <0·0001 0·006 0·56 0·65 <0·0001
Diastolic 0·51 0·002 0 0·99 0·51 0·001
Stroke
Systolic 0·71 <0·0001 0·004 0·48 0·71 <0·0001
Diastolic 0·66 0·0001 0·007 0·55 0·65 <0·0001
Myocardial infarction 
Systolic 0·55 0·001 0·02 0·37 0·53 0·0005
Diastolic 0·54 0·001 0·09 0·06 0·45 0·002
Every metaregression model included blood pressure at entry and blood pressure difference between study groups as independent variables and was weighted by the
inverse of the variance of individual odds ratios. 
Table 3: Variance explained by initial blood pressure and blood pressure difference 
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than their counterparts given old classes of drugs (figure
2): odds ratio 0·80 (0·65–0·99, p=0·04), but this result
did not lead to significant heterogeneity among studies
including calcium-channel blockers. 
After exclusion of ALLHAT,10 overall cardiovascular
risk did not differ between patients randomised to
diuretics or -blockers compared with those allocated
initial treatment with calcium-channel blockers or ACE
inhibitors (figure 1). However, in patients randomised to
calcium-channel blockers, reduction in risk of stroke was
greater (difference 13·5%, 1·3–24·2, p=0·03, figure 2),
but reduction in risk of myocardial infarction was less
(19·2%, 3·5–37·3%, p=0·01, figure 2) than in those in
whom treatment was started with old drugs. In patients
given ACE inhibitors, risk reductions were similar for
stroke and for myocardial infarction (figure 2). 
In trials leading to significant heterogeneity,4,10 or with
significant differences in overall risk of cardiovascular
events10 or cause-specific cardiovascular complications,4,9,10
there were differences in achieved systolic pressure
between groups of 2 mm Hg or more (table 1). Therefore,
we decided to investigate further the relation between
odds ratios expressing benefit and achieved blood
pressure differences by use of most of the published
evidence.
Blood pressure reduction 
The 27 studies in our metaregression included
136 124 patients. These studies consisted of nine
actively controlled trials (table 1);3–6,8–10,14,16 HOT,26 in
which different levels of blood pressure control were
investigated; three placebo-controlled trials in isolated
systolic hypertension;39–41 three placebo-controlled trials
in normotensive or hypertensive patients at high
cardiovascular risk;7,12,15 and 11 older trials testing
efficacy of antihypertensive drugs against no
treatment. The characteristics of these 11 trials have
been reviewed.17,18,20,21,24,25
The metaregression line between odds of an event
and differences in systolic pressure between study
groups was linear for cardiovascular mortality (figure
4) and curvilinear for all cardiovascular events (figure
4), stroke (figure 5), and myocardial infarction
including sudden death (figure 5). Blood pressure at
baseline contributed less to explained variance than
blood pressure differences during follow-up (table 3).
Consequently, adjustment of metaregression lines for
baseline systolic pressure did not substantially alter
their position.
Systolic pressure differences seen in individual
studies are shown in table 1 and figures 4 and 5.
Blood pressure after enrolment was reported at near
mean5,10,12,30–33,49 or median40,41 follow-up in ten trials, at
end of follow-up in four,6,7,36,63 and as average of whole
follow-up in 13.3,8,9,15,16,26,28,29,34,35,37–39 In addition to
ALLHAT,10 CAPPP,4 and NORDIL9 (table 1),
differences in achieved systolic pressure, diastolic
pressure, or both between study groups (reference
minus experimental drug) were significant in
hypertension trials that included less treated26,27 or
untreated28–41 controls, and in MIDAS (difference
3·5 [systolic]/about 0 [diastolic] mm Hg),3 HOPE
(3·3/1·0 mm Hg),7 PART2 (5/4 mm Hg),12
and SCAT (4/2 mm Hg).15 For MIDAS3
combined with NICS5 and VHAS,63 systolic/diastolic
differences were 1·8/about 0 mm Hg. For PART212
combined with SCAT,15 these differences were
4·6/3·1 mm Hg. Differences between observed
odds ratios and those predicted by metaregression
lines (table 4) were not significant apart from in
NORDIL,9 in which risk of stroke was lower in
patients on diltiazem than on old drugs despite
systolic pressure that was 3·1 mm Hg higher on
diltiazem (figure 5 and table 4). ALLHAT10 and
HOPE7 were large trials (table 1) with significant
differences in on-treatment systolic pressure between
randomised groups. STONE34 and Syst-China41 used
alternate non-randomised allocation of consecutive
patients to placebo on active treatment. Sensitivity
analyses in which ALLHAT10 and HOPE,7 or
STONE34 and Syst-China41 were excluded only slightly
changed the position of the regression lines and their
95% CIs, and therefore did not alter the results shown
in table 4.
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Observed odds ratio (95% CIs)* Predicted mean odds ratio (95% CIs)† Difference (% [95% CIs])‡ p§
ALLHAT10
Cardiovascular events 1·24 (1·15–1·33) 1·14 (0·98–1·32) –8·4 (–27·0 to 7·4) 0·32
Stroke 1·18 (0·99–1·39) 1·06 (0·92–1·22) –11·3 (–38·1 to 10·3) 0·33
Myocardial infarction 1·01 (0·88–1·16) 1·13 (0·98–1·31) 10·7 (–8·2 to 26·2) 0·25
CAPPP4
Cardiovascular mortality 0·80 (0·58–1·09) 0·99 (0·81–1·22) 19·8 (–16·1 to 44·6) 0·24
Cardiovascular events 1·10 (0·95–1·27) 1·23 (1·03–1·46) 10·3 (–11·5 to 27·9) 0·33
Stroke 1·29 (1·03–1·61) 1·14 (0·96–1·34) –13·4 (–49·0 to 13·8) 0·37
Myocardial infarction 1·01 (0·80–1·26) 1·21 (1·02–1·44) 17·0 (–9·8 to 37·2) 0·19
HOPE7
Cardiovascular mortality 0·73 (0·62–0·86) 0·86 (0·74–0·99) 14·4 (–5·7 to 30·6) 0·15
Cardiovascular events 0·76 (0·67–0·85) 0·82 (0·75–0·91) 8·4 (–6·2 to 21·0) 0·24
Stroke 0·68 (0·52–0·86) 0·77 (0·69–0·85) 11·1 (–12·3 to 29·6) 0·32
Myocardial infarction 0·79 (0·69–0·90) 0·85 (0·77–0·93) 7·2 (–8·6 to 20·6) 0·35
NORDIL9
Cardiovascular mortality 1·16 (0·89–1·50) 1·00 (0·81–1·22) –16·1 (–60·8 to 16·2) 0·37
Cardiovascular events 1·04 (0·91–1·20) 1·24 (1·04–1·47) 15·5 (–4·8 to 31·9) 0·13
Stroke 0·81 (0·65–1·01) 1·14 (0·97–1·35) 28·8 (6·8 to 45·5) 0·01
Myocardial infarction 1·19 (0·95–1·48) 1·22 (1·02–1·46) 3·0 (–28·1 to 26·5) 0·83
PART2/SCAT12,15
Cardiovascular mortality 0·47 (0·21-0·98) 0·83 (0·73–0·95) 43·3 (–19·8 to 73·2) 0·14
Cardiovascular events 0·64 (0·44-0·94) 0·78 (0·70–0·86) 17·3 (–22·8 to 44·3) 0·35
Myocardial infarction 0·63 (0·38-1·05) 0·80 (0·73–0·88) 21·2 (–31·1 to 52·7) 0·36
*Odds ratio reported in the published articles. †Mean odds ratio (95% CI) predicted by metaregression lines (figures 4 and 5). ‡Difference between predicted minus
observed odds ratio (95% CI) expressed in percent of predicted odds ratio. §Significance of difference between observed and predicted odds ratios. 
Table 4: Observed odds ratios and odds ratios predicted by differences in systolic blood pressure in metaregression
For personal use. Only reproduce with permission from The Lancet Publishing Group.
Discussion
Our main finding was that results of outcome trials
for antihypertensive drugs can be explained by blood
pressure differences between randomised groups. All
antihypertensive drugs had similar long-term efficacy
and safety. Our results show the desirability of
lowering blood pressure as much as possible to
achieve the greatest reduction in cardiovascular
complications. These findings are in accord with, and
add to, earlier reports.17,18 Indeed, in older patients
with isolated systolic hypertension,17 lowering systolic
blood pressure by 10 mm Hg and diastolic
pressure by 4 mm Hg reduced risk of stroke and
myocardial infarction by 30% and 23%, respectively.
In patients with predominantly diastolic hypertension,18
corresponding benefits produced by a 5–6 mm Hg
decline in diastolic pressure were 38% and 16%,
respectively.
Because in most trials study groups were similar
at entry, we did not need to adjust for
characteristics of patients in our metaregression.
Furthermore, blood pressure at entry explained little
additional variance. After adjustment for baseline
blood pressure, our conclusions remained unaltered.
The stage of follow-up at which we assessed blood
pressure differences depended on what was reported
in the studies. However, our inclusion criteria
specified a minimum follow-up of 2 years. In most
trials, blood pressure differences between study
groups were already at their greatest at 6 months
of follow-up. Moreover, our metaregression results
suggested that for fatal and non-fatal outcomes
combined, a substantial part of drug benefit was
already achieved by modest 5 mm Hg differences in
systolic pressure. Almost all possible benefit of
antihypertensive treatment was seen at systolic
pressure gradients of about 15 mm Hg. However,
these results should be interpreted cautiously.
Indeed, these differences in systolic pressure do not
represent absolute declines in blood pressure,
because they were expressed relative to blood
pressure changes in controls. Furthermore, the 5357
patients randomised in trials in which systolic
difference exceeded 15 mm Hg represented only
3·9% of patients included in our metaregression
analysis. We also did not define a priori the
hypothesis of a curvilinear relation between odds
ratios and achieved differences in systolic pressure.
In HOPE7,62 around 90% of patients had previous
cardiovascular complications. Treatment with ramipril
reduced cardiovascular mortality and incidence of
stroke, myocardial infarction, and congestive heart
failure.7 Systolic pressure differed by 3·3 mm Hg
between ramipril and placebo groups.7 Endothelial
actions of ramipril62 have been suggested as
stabilisers of atherosclerotic plaques in the large
arteries.64 ACE inhibitors have proven benefit in
patients with heart failure65 or dysfunction of the left
ventricle.66 However, our results suggest that in fact
blood pressure could have accounted for most—if
not all—benefits seen in HOPE patients allocated
ramipril. Furthermore, results of two further placebo-
controlled trials of ACE inhibition in high-risk
patients12,15 also did not significantly deviate from
benefits predicted by differences in systolic pressure
between randomised groups.
Two large Scandinavian trials4,6 also did not
produce any evidence that ACE inhibitors would
provide better cardiovascular protection than
diuretics, -blockers, or both. By contrast, risk of
stroke was 18% higher in patients randomised to
initial treatment with captopril than in those given
old drugs.4 Interpretation of these results is difficult,
because at randomisation blood pressure was already
2·2/1·7 mm Hg higher in patients in the captopril
group4,57 and the blood pressure gradient was
maintained during follow-up. After extrapolation of
results from the Framingham Heart Study and the
second National Health and Nutrition Examination
Survey,19 researchers speculated that a 2 mm Hg
difference in blood pressure could account for a
15% difference in stroke risk, but they could not
exclude the possibility that old drugs were more
effective in prevention of stroke.4 Our results
suggest that less blood pressure control on captopril
could explain the higher risk of stroke.4
Patients randomly assigned doxazosin had higher
rates of stroke and congestive heart failure than
those on chlorthalidone.10 The investigators suggested
that participants’ blood pressure differences were
sufficient to explain the higher incidence of stroke
on doxazosin, but that these differences could
account for only a 10–20% increase in occurrence
of heart failure—not a doubling of the rate.10 Our
metaregression analysis results showed that the
blood pressure gradient was indeed sufficient to
explain the higher risk of stroke on doxazosin.
Furthermore, before randomisation, 90% of the
patients were on antihypertensive drugs, presumably
diuretics in many instances. Thus, ALLHAT not
only tested doxazosin versus chlorthalidone, but
also tested stopping versus continuing a diuretic in
a group of hypertensive patients, of whom a
considerable proportion must have been at high
risk of heart failure. These factors probably explain
why Kaplan-Meier curves for heart failure started
to diverge immediately after randomisation.10 The
most important point, however, is that doxazosin
achieved similar results to chlorthalidone for the
primary outcome, which was coronary heart
disease, despite poorer blood pressure control on
doxazosin.10
The results of our quantitative overview of
actively controlled trials in hypertension showed
that calcium-channel blockers and ACE inhibitors
reduced fatal and non-fatal outcomes as effectively
as diuretics or -blockers. Compared with older
drug classes, calcium-channel blockers and ACE
inhibitors gave the same overall protection against
cardiovascular complications, but calcium-channel
blockers provided more reduction in risk of stroke
and less reduction in risk of myocardial infarction.
With metaregression, we showed that diltiazem
compared with diuretics, -blockers, or both,
decreased risk of stroke despite higher systolic
pressure. Furthermore, stroke results were not
heterogeneous between NORDIL9 and other actively
controlled studies with calcium-channel blockers.3,5,6,8,63
Nevertheless, these cause-specific results must be
interpreted with caution because confidence intervals
were wide, and because results might be attributable
not only to the drugs under study, but also to
characteristics of patients.67 Selective recruitment of
middle-aged patients with type 2 diabetes,53 older
high-risk hypertensive patients,8 and elderly patients
with isolated systolic hypertension39,40,56,59 probably
explains why rates of myocardial infarction varied
from 6·38 to 32·256 cases per 1000 patient-years,
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and why results for prevention of myocardial
infarction were contradictory.
Our overview should be interpreted within the
context of its limitations. As in all meta-analyses
that start from published summary statistics, we
achieved less standardisation than is attainable in
quantitative overviews based on individual patients’
data. Thus, not only participants’ characteristics, but
also the definition and validation of endpoints in
individual trials might have affected our estimates of
risk in treated and untreated patients. Masked
validation in open trials4,6,9,16,26,28,49 does not remove the
possibility that previous knowledge of treatment
allocation resulted in selective over-reporting or under-
reporting of events. Furthermore, we chose not to
combine weaker coronary endpoints such as angina
pectoris with myocardial infarction, sudden death, or
both. Conversely, to allow interpretation of ALLHAT
results10 against the background of all available
evidence, we included heart failure in all cardiovascular
events, which can also be looked upon as a weaker
clinical endpoint. Finally, our analysis does not
indicate to what extent blood pressure should be
lowered. This issue remains unsettled because the
studies that we analysed did not account for systolic
pressure or pulse pressure,26,49 or had blood pressure
targets that were too high.27 Additionally, individual
tailoring of antihypertensive drugs compared with fixed
selection, titration, and combination of treatments was
not investigated in any trial.
In conclusion, in trials in hypertension and high-
risk patients, blood pressure gradients largely
accounted for most differences in outcome. These
findings emphasise the desirability of blood pressure
control. On average, all antihypertensive drugs have
similar long-term efficacy and safety. Compared
with diuretics and -blockers, calcium-channel
blockers might protect more against stroke than
myocardial infarction, resulting in an overall
cardiovascular benefit similar to that of old classes
of antihypertensive drugs. The hypothesis that in the
reviewed studies ACE inhibitors might affect
outcome beyond their blood-pressure-lowering effects
remains unproved. On the contrary, in the
PROGRESS trial,68 monotherapy with perindopril
lowered systolic pressure by 5 mm Hg more
than placebo, but unexpectedly69 did not reduce the
risk of cardiovascular events or stroke recurrence.
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Appendix
ABCD (Appropriate Blood Pressure Control in Diabetes trial);53
ALLHAT (Antihypertensive and Lipid-Lowering Treatment to
Prevent Heart Attack Trial);10,58 ATMH (Australian Trial in Mild
Hypertension);35 CAPPP (Captopril Prevention Project);4,57 EWPHE
(trial conducted by the European Working Party on High Blood
Pressure in the Elderly);30,55 HEP (trial of hypertension in elderly
patients in primary care);28 HDFP (Hypertension Detection and
Follow-Up Program);49 HOPE (Heart Outcomes Prevention
Evaluation Study);7,62 HOT (Hypertension Optimal Treatment trial);26
HOT M vs H (Hypertension Optimal Treatment trial—85 vs 90 mm
Hg as target diastolic pressure);26 HOT L vs H (Hypertension
Optimal Treatment trial—80 vs 90 mm Hg as target diastolic
pressure);26 HSCS (Hypertension-Stroke Cooperative Study);36
INSIGHT (International Nifedipine GITS Study—Intervention as a
Goal in Hypertensive Treatment);8 MIDAS (Multicenter Isradipine
Diuretic Atherosclerosis Study);3 MIDAS/NICS/VHAS (combined
results of MIDAS,3 NICS,5 and VHAS63); MRC1 (Medical Research
Council trial of treatment of mild hypertension);33 MRC2 (Medical
Research Council trial of treatment of hypertension in older adults);32
NORDIL (Nordic Diltiazem Study);9 NICS (National Intervention
Cooperative Study in Elderly Hypertensives);5 OSLO (Oslo Study on
the Treatment of Mild Hypertension);29 PART2 (Prevention of
Atherosclerosis with Ramipril Trial);12 PART2/SCAT (combined
results of PART212 and SCAT15); RCT70-80 (combined results of 4
smaller trials published from 1970 through 1980, including HSCS,36
OSLO,29 USPHS,37 and VACS38); SCAT (Simvastatin/Enalapril
Coronary Atherosclerosis Trial);15 SHEP (Systolic Hypertension in the
Elderly Program);39,56 STONE (Shanghai Trial of Nifedipine in the
Elderly);34 STOP1 (Swedish Trial in Old Patients with
hypertension);31 STOP2 (Swedish Trial in Old Patients with
hypertension-2);6 STOP2/ACEIs (angiotensin-converting enzyme
inhibitor arm of STOP2);6 STOP2/CCBs (calcium-channel blocker
arm of STOP2);6 Syst-China (Systolic Hypertension in China
trial);41,61 Syst-Eur (Systolic Hypertension in Europe trial);40,59,60
UKPDS (UKPDS Hypertension in Diabetes Study);16,27 UKPDS C vs
A (UKPDS Hypertension in Diabetes Study–captopril vs atenolol);16
UKPDS L vs H (UKPDS Hypertension in Diabetes Study—low vs
high on-treatment blood pressure);27 USPHS (United States Public
Health Service Hospitals Cooperative Study);37 VACS (Veterans
Administration Cooperative Study in patients with diastolic blood
pressure averaging 90–114 mm Hg);38 VHAS (Verapamil in
Hypertension and Atherosclerosis Study).63
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